This article is a correction to:
Toxicity profile of combined immune checkpoint inhibitors and thoracic radiotherapy in esophageal cancer: A meta-analysis and systematic review
Tongzhen Xu
Yunsong Liu
Xiaotong Lu
Jun Liang- 1Department of Radiotherapy Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- 2Department of Radiotherapy Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China
A corrigendum on
Toxicity profile of combined immune checkpoint inhibitors and thoracic radiotherapy in esophageal cancer: A meta-analysis and systematic review
by Xu T, Liu Y, Lu X and Liang J (2022) Front. Immunol. 13:1039020. doi: 10.3389/fimmu.2022.1039020
In the published article, there was an error. Two words were misspelled.
A correction has been made to Conclusions, Paragraph One. This sentence previously stated:
“Compared with PD-1 inhibitors, PD-L1 inhibitors might increase the incidence of any-grade pneumonitis.”
The corrected sentence appears below:
“Compared with PD-L1 inhibitors, PD-1 inhibitors might increase the incidence of any-grade pneumonitis.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: esophageal cancer, safety, toxicity profile, immune checkpoint inhibitors, thoracic radiotherapy, systemic analysis
Citation: Xu T, Liu Y, Lu X and Liang J (2023) Corrigendum: Toxicity profile of combined immune checkpoint inhibitors and thoracic radiotherapy in esophageal cancer: A meta-analysis and systematic review. Front. Immunol. 14:1193710. doi: 10.3389/fimmu.2023.1193710
Received: 25 March 2023; Accepted: 30 March 2023;
Published: 11 April 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Xu, Liu, Lu and Liang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jun Liang, liang23400@163.com